Lilly faces setback as FDA pushes back Bydureon to 2012
This article was originally published in Scrip
Executive Summary
Lilly has suffered another blow to its late-stage pipeline after the US FDA unexpectedly issued another complete response letter for Bydureon, Lilly/Amylin/Alkermes' once-weekly formulation of the twice-daily injectable type 2 diabetes drug Byetta (exenatide).